Your browser is no longer supported. Please, upgrade your browser.
Silverback Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own8.34% Shs Outstand34.88M Perf Week-5.26%
Market Cap318.42M Forward P/E- EPS next Y-3.18 Insider Trans0.00% Shs Float32.12M Perf Month-17.58%
Income- PEG- EPS next Q-0.67 Inst Own86.30% Short Float12.53% Perf Quarter-70.46%
Sales- P/S- EPS this Y-31.00% Inst Trans0.07% Short Ratio9.51 Perf Half Y-74.08%
Book/sh10.03 P/B0.90 EPS next Y-21.20% ROA- Target Price45.40 Perf Year-
Cash/sh10.17 P/C0.89 EPS next 5Y- ROE- 52W Range8.88 - 63.41 Perf YTD-80.58%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.81% Beta-
Dividend %- Quick Ratio23.30 Sales past 5Y- Gross Margin- 52W Low1.35% ATR0.80
Employees76 Current Ratio23.30 Sales Q/Q- Oper. Margin- RSI (14)29.10 Volatility5.76% 8.63%
OptionableYes Debt/Eq0.00 EPS Q/Q-362.70% Profit Margin- Rel Volume1.61 Prev Close9.03
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume423.12K Price9.00
Recom1.60 SMA20-8.62% SMA50-44.09% SMA200-72.11% Volume679,773 Change-0.33%
Dec-29-20Initiated SVB Leerink Outperform $40
Dec-29-20Initiated Stifel Buy $58
Dec-29-20Initiated H.C. Wainwright Buy $44
Dec-29-20Initiated Goldman Buy $43
Oct-05-21 08:00AM  
Oct-03-21 08:41PM  
Oct-01-21 04:07PM  
Sep-27-21 09:30PM  
Sep-24-21 08:01AM  
Sep-21-21 05:56PM  
Sep-19-21 11:23PM  
Sep-17-21 03:30PM  
Sep-16-21 07:45AM  
Sep-14-21 08:03PM  
Sep-13-21 08:00AM  
Sep-07-21 04:25PM  
Aug-31-21 09:53AM  
Aug-12-21 04:05PM  
Aug-03-21 08:00AM  
Jul-21-21 11:51AM  
Jul-07-21 07:30AM  
Jun-15-21 08:00AM  
Jun-02-21 06:13AM  
Jun-01-21 07:59AM  
May-13-21 04:05PM  
Apr-26-21 01:29AM  
Apr-08-21 08:00AM  
Mar-29-21 04:05PM  
Mar-15-21 08:00AM  
Mar-04-21 03:20AM  
Feb-16-21 08:00AM  
Dec-29-20 05:56PM  
Dec-16-20 04:52PM  
Dec-08-20 05:00PM  
Dec-04-20 04:30PM  
Dec-03-20 10:44PM  
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Presidio Management Group XII,10% OwnerDec 08Buy21.0047,619999,99947,619Dec 08 09:04 PM
CAPPS VICKIE LDirectorDec 08Buy21.009,523199,98361,576Dec 08 08:56 PM
Hawkinson RussSr. Vice President of FinanceDec 08Buy21.002384,998238Dec 08 08:52 PM
Piazza JonathanChief Financial OfficerDec 08Buy21.0011,904249,98411,904Dec 08 08:50 PM
Schroeder ThiloDirectorDec 08Buy21.00238,0965,000,016238,096Dec 08 08:48 PM
ROOT JONATHAN DDirectorDec 08Buy21.0095,2381,999,99895,238Dec 08 08:46 PM
Thompson Peter A.DirectorDec 08Buy21.001,190,47725,000,017952,377Dec 08 08:43 PM
ORBIMED ADVISORS LLCDirectorDec 08Buy21.001,190,47725,000,017952,377Dec 08 08:41 PM